GlassScriptPhysician profile
James A Rice
NPI 1760417513
$5,766.88
in general payments reported to CMS, 2019-2025
37 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $709 · 2021: $1,152 · 2022: $790 · 2023: $285 · 2024: $796 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,641.28 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,257.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $818.09 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $173.14 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $142.01 | 2021-2025 | Rexulti, Abilify Maintena |
| Merck Sharp & Dohme LLC | $137.74 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $113.57 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.55 | 2019-2022 | |
| Dexcom, INC. | $102.11 | 2021-2022 | |
| Pfizer INC. | $101.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $98.78 | 2019-2024 | |
| Abbott Laboratories | $93.33 | 2021-2022 | |
| Astellas Pharma US INC | $88.99 | 2021 | |
| Glaxosmithkline, LLC. | $82.72 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Mylan Specialty L.P. | $79.74 | 2021-2023 | Yupelri |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.